000107395 001__ 107395
000107395 005__ 20240104111815.0
000107395 0247_ $$2doi$$a10.1111/bph.15276
000107395 0248_ $$2sideral$$a120102
000107395 037__ $$aART-2021-120102
000107395 041__ $$aeng
000107395 100__ $$0(orcid)0000-0002-7477-8742$$aManzano, Raquel$$uUniversidad de Zaragoza
000107395 245__ $$aWhat skeletal muscle has to say in amyotrophic lateral sclerosis: implications for therapy
000107395 260__ $$c2021
000107395 5060_ $$aAccess copy available to the general public$$fUnrestricted
000107395 5203_ $$aAmyotrophic lateral sclerosis (ALS) is an adult onset disorder characterised by progressive neuromuscular junction (NMJ) dismantling and degeneration of motor neurons leading to atrophy and paralysis of voluntary muscles responsible for motion and breathing. Except for a minority of patients harbouring genetic mutations, the origin of most ALS cases remains elusive. Peripheral tissues, and particularly skeletal muscle, have lately demonstrated an active contribution to disease pathology attracting a growing interest for these tissues as therapeutic targets in ALS. In this sense molecular mechanisms essential for cell and tissue homeostasis have been shown to be de‐regulated in the disease. These include muscle metabolism and mitochondrial activity, RNA processing, tissue‐resident stem cell function responsible for muscle regeneration, and proteostasis that regulates muscle mass in adulthood.
This review aims to compile scientific evidence that demonstrates the role of skeletal muscle in ALS pathology and serve as reference for development of novel therapeutic strategies targeting this tissue to delay disease onset and progression.
000107395 536__ $$9info:eu-repo/grantAgreement/ES/FIS-FEDER/PI17-00949$$9info:eu-repo/grantAgreement/EC/H2020/752349 /EU/Nanoparticle-based immunization, a novel therapeutic strategy for amyotrophic lateral sclerosis/NanoALS$$9This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 752349-NanoALS
000107395 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000107395 590__ $$a9.473$$b2021
000107395 591__ $$aPHARMACOLOGY & PHARMACY$$b18 / 279 = 0.065$$c2021$$dQ1$$eT1
000107395 594__ $$a13.6$$b2021
000107395 592__ $$a1.993$$b2021
000107395 593__ $$aPharmacology$$c2021$$dQ1
000107395 655_4 $$ainfo:eu-repo/semantics/review$$vinfo:eu-repo/semantics/acceptedVersion
000107395 700__ $$0(orcid)0000-0002-7243-1737$$aToivonen, Janne Markus$$uUniversidad de Zaragoza
000107395 700__ $$0(orcid)0000-0002-7277-4318$$aMoreno-Martínez, Laura$$uUniversidad de Zaragoza
000107395 700__ $$0(orcid)0000-0002-7955-7164$$ade la Torre, Miriam$$uUniversidad de Zaragoza
000107395 700__ $$0(orcid)0000-0003-2436-7205$$aMoreno-García, Leticia$$uUniversidad de Zaragoza
000107395 700__ $$0(orcid)0000-0001-9802-8199$$aLópez-Royo,Tresa$$uUniversidad de Zaragoza
000107395 700__ $$aMolina, Nora
000107395 700__ $$0(orcid)0000-0001-5740-0185$$aZaragoza, Pilar$$uUniversidad de Zaragoza
000107395 700__ $$0(orcid)0000-0001-5193-7782$$aCalvo, Ana Cristina$$uUniversidad de Zaragoza
000107395 700__ $$0(orcid)0000-0001-5687-6704$$aOsta, Rosario$$uUniversidad de Zaragoza
000107395 7102_ $$11001$$2420$$aUniversidad de Zaragoza$$bDpto. Anatom.,Embri.Genét.Ani.$$cÁrea Genética
000107395 7102_ $$11012$$2315$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Farmacología
000107395 773__ $$g178, 6 (2021), 1279-1297$$pBr. J. Pharmacol.$$tBRITISH JOURNAL OF PHARMACOLOGY$$x0007-1188
000107395 8564_ $$s1296837$$uhttps://zaguan.unizar.es/record/107395/files/texto_completo.pdf$$yPostprint
000107395 8564_ $$s1860461$$uhttps://zaguan.unizar.es/record/107395/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000107395 909CO $$ooai:zaguan.unizar.es:107395$$particulos$$pdriver
000107395 951__ $$a2024-01-04-11:04:36
000107395 980__ $$aARTICLE